Stoner, Marie C. D. http://orcid.org/0000-0002-7189-8669
Hawley, Imogen
Mathebula, Florence
Horne, Elizea
Etima, Juliane
Kemigisha, Doreen
Mutero, Prisca
Dandadzi, Adlight
Seyama, Linly
Fabiano, Zayithwa
Scheckter, Rachel
Noguchi, Lisa
Owor, Maxensia
Balkus, Jennifer E.
Montgomery, Elizabeth T.
Funding for this research was provided by:
National Institute of Nursing Research (UM1AI068633, UM1AI068615, UM1AI106707)
Article History
Accepted: 1 July 2023
First Online: 11 July 2023
Declarations
:
: The authors have not disclosed any competing interests.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the following Institutional Review Boards/Ethics Committees and Drug Regulatory Authorities: Prevention Sciences Research Committee of the US National Institute of Allergy and Infectious Diseases; US Food and Drug Administration; College of Medicine Research and Ethics Committee; Johns Hopkins School of Public Health Institutional Review Board; Pharmacy, Medicines and Poisons Board of Malawi; Human Research Ethics Committee: (Medical), University of Witwatersrand, Johannesburg; South African Health Products Regulatory Authority; Joint Clinical Research Centre Institutional Review Board; Uganda National Council for Science and Technology; Johns Hopkins Medicine Office of Human Subjects Research Institutional Review Board; National Drug Authority of Uganda; Medical Research Council of Zimbabwe; Joint Research Ethics Committee for the University of Zimbabwe Faculty of Medicine and Health Sciences and Parirenyatwa Group of Hospitals; Research Council of Zimbabwe; Medicines Control Authority of Zimbabwe.
: All participants provided informed consent for the study.
: The DVRs used in this study were developed and supplied by the International Partnership for Microbicides (IPM). Oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) was donated by Gilead Sciences.